%0 Case Reports
%T Trabectedin and Radiotherapy in Endometrial Stromal Sarcoma: A Case Report.
%A Carrasco García I
%A Benedetti Pedroza J
%A Miras Rodriguez I
%A Rincón I
%J Case Rep Oncol
%V 17
%N 1
%D 2024 Jan-Dec
%M 38213958
暂无%R 10.1159/000535747
%X <B>UNASSIGNED: </B>Endometrial stromal sarcoma (ESS) is a rare tumor that remains a diagnostic and therapeutic challenge to physicians worldwide. The metastatic setting implies a poor prognosis, with a 5-year survival rate below 40%. Patients with advanced-stage high-grade ESS (HG-ESS) have limited therapeutic options, often involving various chemotherapy regimens.<BR><B>UNASSIGNED: </B>This report depicts the case of a 47-year-old female diagnosed with HG-ESS. She underwent several lines of treatment starting with radiotherapy and brachytherapy, followed by multiple lines of treatment including trabectedin over several months. After retreatment with trabectedin and achieving disease stabilization for 10 months, treatment was optimized by trabectedin combined with radiotherapy, leading to stable disease that is still ongoing and lasts for over 17 months.<BR><B>UNASSIGNED: </B>Our case underscores the challenging nature of treating patients with HG-ESS and highlights the safety of long-term retrial with trabectedin, coupled with radiotherapy administration. This approach maintained a durable stable disease response in the metastatic setting.